About Repligen
Repligen is a publicly listed company based in Waltham (United States) founded in 1981 by Paul Schimmel and Alexander Rich. Products and services for biologic drug manufacturing are supplied. The company has 1,780 employees. Repligen has completed 12 acquisitions, including ARTeSYN, ATOLL-bio and Avitide. Its chief executive, as recorded, is Olivier Loeillot. Its website repligen.com draws about 69 thousand monthly visits. Its Indian entity Repligen India Private Limited reported revenue of ₹110 Cr. Repligen offers products and services including XCell ATF, KrosFlo TFF Systems, and OPUS Pre-packed Columns. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Repligen was founded in 1981 and is headquartered in Waltham, United States. Bioprocessing technologies and reagents for the production of biologic drugs, including monoclonal antibodies, are developed and manufactured by the company. Key offerings include Protein A for antibody purification, growth factor products, and OPUS single-use chromatography columns. Operations focus on supporting purification processes in the biopharmaceutical sector.
- Headquarters Waltham, United States
- Employees 1,780
- Founders Paul Schimmel, Alexander Rich
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website repligen.com
- Social LinkedIn X YouTube
- Legal Name Repligen Corporation
- Indian entity revenue₹110 Cr
FY 2025 · +48% YoY
- Indian entity net profit₹7.66 Cr
FY 2025 · 7% margin
- Indian entity EBITDA₹10.54 Cr
FY 2025 · 10% margin
- Latest Funding Round$238.59M (USD), Post-IPO
Aug 2017
- Investors
- Employee Count1,780
- Investments & AcquisitionsARTeSYN
& 11 more
Associated legal entities of Repligen
Repligen operates through Repligen India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Repligen India Private Limited CIN U29300KA2016FTC086606 | Active | 03 Mar 2016 | Bangalore, Karnataka | ₹110 Cr | 21 | 2 | View details |
Products & Services of Repligen
Repligen offers a comprehensive portfolio of products and services, including XCell ATF, KrosFlo TFF Systems, and OPUS Pre-packed Columns.
Technology for cell culture intensification in bioprocessing
Systems for tangential flow filtration in drug manufacturing
Columns for efficient protein purification processes
Apps and channels of Repligen
its YouTube channel Repligen has 1.1K subscribers and 30 videos.
Videos from Repligen
The most watched videos on Repligen's YouTube channel, Repligen (1.1K subscribers). Click a video to play it here.
More on Repligen.
Funding Insights of Repligen
- Total Rounds 4
- Last Round Post-IPO — $238.59M
- First Round $1.4M
(Dec 2010)
- Investors Count 1
All 4 funding rounds of Repligen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2017 | $238.59M | Post-IPO | – | – | – |
| May 2016 | $100M | Post-IPO | – | – | – |
| Jun 2014 | $4M | Post-IPO | – | – | – |
| Dec 2010 | $1.4M | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Repligen
Repligen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Muscular Dystrophy Association.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A community foundation dedicated to advancing cures for neuromuscular diseases. | 1950 | mda.org | Chicago, United States |
Investor details for Repligen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Repligen India Private Limited (Repligen)
Repligen India Private Limited is the primary company behind Repligen. The board of Repligen India Private Limited currently have 2 directors; the longest-serving is Vijay David Williams Sugumar, appointed in 2022. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vijay David Williams Sugumar DIN 09642657 | Director | 22 Jun 2022 | 4 yrs 4 mo | Repligen India Private Limited |
| Narasimha Murthy Sathyanarayana DIN 10712643 | Director | 22 Jul 2024 | 2 yrs 3 mo | Repligen India Private Limited |
People of Repligen
280 people are tracked at Repligen (113 in leadership, 12 in board & advisors, 155 in team); the tracked headcount is 1,780.
| Name | Role | Group |
|---|---|---|
Paul Schimmel | Co-Founder | Leadership |
Alexander Rich | Co-Founder | Leadership |
Olivier Loeillot | CEO | Leadership |
Kola Otitoju | Senior Vice President, Strategy and Business Development | Leadership |
Mitchell Snyder | Associate Director, Applications Engineering | Leadership |
Arnoud van Leenen | Director EU Controller | Leadership |
| Senior Director - Asia Pacific | Leadership | |
Derek Carroll | Director Of R&d | Leadership |
Derek Masser | Director, Business And Market Development - NMS & EMT | Leadership |
Gentian Mihali | Associate Manufacturing Director | Leadership |
Umay Saplakoğlu | VP, Proteins & Incubator | Leadership |
Herb Boge | Site Qa/qc Director | Leadership |
Jennifer Carmichael | Director | Leadership |
Tejinder Kohli | Director Quality Management | Leadership |
Ralf Kuriyel | Senior Vice President, Research and Development | Leadership |
James Peyser | Vice President - Research And Development | Leadership |
Patricia Chamard | Director, Global Strategic Partnerships | Leadership |
Christopher Dunn | Associate Director Project Management -tff Systems | Leadership |
Danielle Nixon | Director, Market Research And Strategy | Leadership |
Robin Butler | Global Strategic Marketing Director, Upstream Bioprocessing | Leadership |
260 more people are available in the full profile.
Complete people profiles for Repligen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Repligen
Repligen is a publicly listed company on the NASDAQ with ticker symbol RGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Apr 1990
- Listed onNASDAQ: RGEN
- Listed entityRepligen Corporation
- Exchange sectorHealth technology
- ISINUS7599161095
- Share price$175.42 (+1.69% on the day) · 2026-10-13
- Market capitalisation$11.14B
- Price to earnings239.1
- EPS (diluted, trailing year)$0.73
- Volume (last session)1,259,264
Financials of Repligen
Figures of Repligen India Private Limited, the primary company behind Repligen, for FY 2025. Revenue was ₹110 Cr (+48% year on year). Net profit was ₹7.66 Cr (7% margin). EBITDA was ₹10.54 Cr (10% margin). Revenue has grown at a compounded annual rate of +31% over three years and +72% over five years.
- ₹110 CrRevenue · FY 2025 · +48% YoY
- ₹7.66 CrNet profit · 7% margin
- ₹10.54 CrEBITDA · 10% margin
- ₹2.00 CrPaid-up capital
- 21Employees (provident fund records)
- +31%Revenue CAGR, 3 years
- +72%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $738.3M | $48.9M | $158.2M |
| 2024 | $634.4M | -$25.5M | $109.2M |
| 2023 | $632.4M | $35.6M | $135.4M |
| 2022 | $801.5M | $186.0M | $252.9M |
| 2021 | $670.5M | $128.3M | $231.7M |
Balance sheet, profit and loss, cash flow and ratios of Repligen India Private Limited are on its company page.
Detailed financial statements for Repligen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Repligen
Repligen has strategically engaged in corporate development activities, having acquired 12 companies. Notable acquisitions include ARTeSYN, ATOLL-bio and Avitide.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Tissue hypothermic storage and cryopreservation freeze media are developed. | biolifesolutions.com | Bothell, United States | 1987 | Jul 2026 | $1.5B | |
Tools for self-assembly based ordered nanostructures are developed. | tantti.com | Taoyuan, Taiwan | 2014 | Jul 2024 | •••• | |
Magnetic mixers are produced for pharmaceutical and biotechnology sectors. | metenova.com | Molndal, Sweden | 2009 | Sep 2023 | •••• | |
Affinity purification solutions are developed for biopharmaceutical applications. | avitide.com | Lebanon, United States | 2012 | Sep 2021 | $150M | |
Wastewater treatment services are provided for industrial and municipal needs. | polymem.fr | Castanet Tolosan, France | 1997 | Jun 2021 | •••• | |
Disposable fluid management systems for bioprocessing are developed and manufactured. | artesynbiosolutions.com | Waterford, Ireland | 2012 | Oct 2020 | •••• | |
Manufacturer of process deployment aids, thermoplastic tanks, and packaging containers | nonmetallicsolutions.com | Auburn, United States | 2006 | Oct 2020 | •••• | |
Silicon molded products are manufactured for biopharmaceutical applications. | engineeredmolding.com | Clifton Park, United States | 2010 | Jun 2020 | •••• | |
Medical device outsourcing services are provided to clients. | ctechnologiesinc.com | Bridgewater, United States | 1985 | Apr 2019 | $240M | |
Products for bioseparation and cell line management | spectrumlabs.com | Compton, United States | 1970 | Jun 2017 | $359M |
Complete acquisition details for Repligen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Repligen
14 dated milestones of Repligen across 45 years, from founding to its latest funding, stage changes and deals.
- Founded Repligen is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.4M.
- Acquisition Acquires Spectrum Labs.
- Funding Latest funding round, Post-IPO, of $238.6M.
- Acquisition Acquires Repligen.
- Acquisition Acquires Engineered Molding Technology.
- Acquisition Acquires ARTeSYN.
- Acquisition Acquires Non-Metallic Solutions.
- Acquisition Acquires Polymem.
- Acquisition Acquires Avitide.
- Acquisition Acquires Metenova.
- Acquisition Acquires Tantti.
- Acquisition Acquires BioLife Solutions.
Competitors of Repligen
Repligen has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Repligen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Repligen
The website of Repligen (repligen.com) receives about 69.1K visits a month and ranks #392,602 among all websites worldwide, #338 in Biotechnology and Pharmaceuticals.
- Monthly visits69.1K
▼ 14% vs previous month
- Unique visitors32.8K
per month
- Global rank#392,602
among all websites
- Category rank#338
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit3.1
- Average visit54 sec
- DevicesDesktop 32% · Mobile 68%
Websites whose visitors overlap most with Repligen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ligand.com | 100% | 7K | #3,254,882 | View details | |
| spectrumchemical.com | 94% | #387,330 | View details | ||
| sinobiopharm.com | 85% | 11.7K | #2,827,230 | View details | |
| hgsi.com | 85% | View details | |||
| biotech-concepts.com | 85% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 20 similar websites and full traffic analytics for Repligen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Repligen (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Repligen
Complete news archive for Repligen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Repligen
Repligen was founded in 1981 and raised its 1st funding round 29 years after it was founded.
Repligen is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Olivier Loeillot is the CEO of Repligen, as recorded in our data.
Repligen has 1,780 employees.
The primary company behind Repligen, Repligen India Private Limited, reported revenue of ₹110 Cr for FY 2025, up 48% year on year.
Repligen was founded in 1981 and is headquartered in Waltham, United States. Bioprocessing technologies and reagents for the production of biologic drugs, including monoclonal antibodies, are developed and manufactured by the company. Key offerings include Protein A for antibody purification, growth factor products, and OPUS single-use chromatography columns. Operations focus on supporting purification processes in the biopharmaceutical sector.
Repligen's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Repligen offers XCell ATF, KrosFlo TFF Systems, and OPUS Pre-packed Columns.
Yes, Repligen is publicly traded on NASDAQ under the ticker symbol RGEN.
Repligen has 1 investor. Key investors include Muscular Dystrophy Association.
Repligen operates through Repligen India Private Limited.